000 02588nam a2200457 i 4500
999 _c273173
_d273173
001 on1042815421
003 OCoLC
005 20180815084700.0
007 he bmb024bbca
008 180705s2017 dcu bb f000 0 eng c
040 _aPUCPR
_beng
_erda
_cGPO
_dMvI
042 _apcc
043 _an-us---
074 _a1016-B (MF)
086 0 _aY 4.G 74/7:115-33
088 _aSerial no. 115-33 (United States. Congress. House. Committee on Oversight and Government Reform)
099 _aY 4.G 74/7:115-33
110 1 _aUnited States.
_bCongress.
_bHouse.
_bCommittee on Oversight and Government Reform.
_bSubcommittee on Health Care, Benefits, and Administrative Rules,
245 1 0 _aExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain :
_bhearing before the Subcommittee on Healthcare, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, March 22, 2017.
264 1 _aWashington :
_bU.S. Government Publishing Office,
_c2017.
300 _aiii, 54 pages ;
_c24 cm
336 _btxt
337 _bh
_2rdamedia
338 _bhe
_2rdacarrier
500 _a"Serial no. 115-33."
500 _aShipping list no.: 2018-0099-M.
500 _aCRDP Program record.
504 _aIncludes bibliographical references.
533 _aMicrofiche.
_b[Washington, D.C.] :
_cU.S. Government Printing Office,
_d[2018]
_e1 microfiche : negative.
776 0 8 _iPrint version:
_aUnited States. Congress. House. Committee on Oversight and Government Reform. Subcommittee on Health Care, Benefits, and Administrative Rules.
_tExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain
_w(DLC) 2017415181
_w(OCoLC)1013554615
776 0 8 _iOnline version:
_aUnited States. Congress. House. Committee on Oversight and Government Reform. Subcommittee on Health Care, Benefits, and Administrative Rules.
_tExamining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain
_w(OCoLC)1013542208
050 4 _aKF27
_b.O9435 2017c
650 0 _aPharmaceutical industry
_xCorrupt practices
_zUnited States.
650 0 _aPharmaceutical policy
_zUnited States.
650 0 _aGeneric drugs
_xDevelopment
_zUnited States.
650 0 _aPrescription pricing
_zUnited States.
650 0 _aCompetition
_zUnited States.
650 0 _aConsumer protection
_zUnited States.
655 7 _aLegislative hearings.
_2lcgft
942 _2sudocs
_c8